Sign in

IBO on NYSE

IMPACT BIOMEDICAL INC.

American pharmaceutical preparations company, incorporated in Nevada1

In its 2026 annual report the company says: “We are the sole owner of the issued and outstanding common stock of Impact BioLife Science, Inc. We own approximately 95.5% of the issued and outstanding common stock of Sweet Sense.”4 It is headquartered in West Henrietta, New York.1 Its shares trade on NYSE under the symbol IBO.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Rafael Holdings, Inc., Lyell Immunopharma, Inc. or AcelRx Pharmaceuticals (United States), or pick any stock.

  • TickerIBO on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWest Henrietta, New York1
  • Incorporated inNV2
  • Business address275 Wiregrass Pkwy,, West Henrietta, Ny 145862
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

(i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) Impact BioLife Science, Inc.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-13381.2%Operating margin5
-36993.8%Net margin5
-93.9%Return on equity5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue8¢$424.0K
  • Research and development7¢$340.0K
  • Selling, general and admin17¢$873.0K
  • Interest16¢$793.0K
  • Income tax51¢$2.6M

Out of $32.0K in revenue.5 The company lost money this year.

Financial statements

Revenue65$32.0K in 2025−36% since 2022
0$20.0K$40.0K$60.0K2022: $50.0K$50.0K20222025: $32.0K$32.0K2025−36%
Operating income675-$4.3M in 2025+26% since 2022
-$30.0M-$20.0M-$10.0M02022: -$3.4M-$3.4M20222023: -$4.0M-$4.0M2023+18%2024: -$28.8M-$28.8M2024+614%2025: -$4.3M-$4.3M2025−85%
Net income675-$11.8M in 2025+63% since 2022
-$30.0M-$20.0M-$10.0M02022: -$7.3M-$7.3M20222023: -$4.3M-$4.3M2023−40%2024: -$24.7M-$24.7M2024+470%2025: -$11.8M-$11.8M2025−52%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Total revenue$32.0K
Cost of revenue$424.0K
Sales, general and administrative compensation (inclusive of stock-based compensation)$873.0K$718.0K
Sales and marketing$24.0K$633.0K
Professional Fees$1.0M$446.0K
Research and development$340.0K$278.0K
Depreciation and Amortization$1.1M$1.1M
Rent and utilities$74.0K$32.0K
Impairment of goodwill$25.1M
Impairment of fixed assets$263.0K
Loss on disposal of fixed assets$12.0K
Other operating expenses$417.0K$171.0K
Total costs and expenses$4.3M$28.8M
Operating loss-$4.3M-$28.8M
Interest income$13.0K$13.0K
Change in fair value of note payable, related party-$9.4M$5.1M
Interest expense-$793.0K-$1.1M
Loss from operations before income taxes-$14.4M-$24.7M
Income tax benefit (expense)$2.6M-$33.0K
Net loss-$11.9M-$24.8M
Loss from operations attributed to noncontrolling interest$32.0K$62.0K
Net loss attributable to common stockholders-$11.8M-$24.7M
Basic-$0.38-$2.30
Diluted-$0.38-$2.30
Basic31.6M shares10.8M shares
Diluted31.6M shares10.8M shares

Compare IMPACT BIOMEDICAL INC. with another company

Corporate structure

IMPACT BIOMEDICAL INC. is part of a group headed by DSS, INC.. 33 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of IMPACT BIOMEDICAL INC.

  • Fai Chan Filed SCHEDULE 13D/A on IMPACT BIOMEDICAL INC., latest Apr 4, 2025 (2 filings since Apr 2, 2025)
  • DSS, INC. West Henrietta, New York
    • IMPACT BIOMEDICAL INC. West Henrietta, New York
      • Global Sugar Solutions, Inc. Subsidiary · Nevada, United States
    • Alset Innovations, Inc. Subsidiary · Texas, United States
    • American First Wealth Management, Inc. (formally DSS Wealth Management, Inc.) Subsidiary · Texas, United States
    • American Pacific Financial Subsidiary · Texas, United States
    • AMRE Asset Management, Inc. Subsidiary · Nevada, United States
    • BioLife Sugar, Inc. Subsidiary · Nevada, United States
    • Decentralized Sharing Systems, Inc. Subsidiary · Nevada, United States
    • DSS Administrative Group, Inc. Subsidiary · New York, United States
    • DSS Asset Management, Inc. Subsidiary · Texas, United States
    • DSS BioHealth Security, Inc. Subsidiary · Nevada, United States
    • DSS Biolife International, Inc. Subsidiary · Nevada, United States
    • DSS BioMedical International, Inc. Subsidiary · Nevada, United States
    • DSS Blockchain Security, Inc. Subsidiary · Nevada, United States
    • DSS Financial Management, Inc. Subsidiary · Texas, United States
    • DSS PureAir, Inc. Subsidiary · Texas, United States
    • DSS Robot, Inc. Subsidiary · Nevada, United States
    • DSS Securities, Inc. Subsidiary · Nevada, United States
    • DSS Technology Management, Inc. Subsidiary · Nevada, United States
    • Gigenomics Solutions, Inc Subsidiary · Texas, United States
    • Global BioLife, Inc. Subsidiary · Texas, United States
    • Global BioMedical, Inc. Subsidiary · Nevada, United States
    • Happy Sugar, Inc. Subsidiary · Nevada, United States
    • HWH World, Inc. Subsidiary · Texas, United States
    • Impact BioLife Science, Inc. Subsidiary · Nevada, United States
    • Impact Oncology Pte Subsidiary · Nevada, United States
    • and 6 more

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IMPACT BIOMEDICAL INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$30.0K5 Dec 31, 2024$293.0K7 Dec 31, 2023−89.8%
Accumulated depreciation$13.0K5 Dec 31, 2024$6.0K7 Dec 31, 2023+116.7%
Property and equipment, net$17.0K5 Dec 31, 2024$287.0K7 Dec 31, 2023−94.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.0K5 Dec 31, 2025$2.0M5 Dec 31, 2024−99.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$22.6M5 Dec 31, 2025$22.3M5 Dec 31, 2024+1.5%
Accumulated amortization$5.6M5 Dec 31, 2025$4.5M5 Dec 31, 2024+25.6%
Finite-lived intangibles, net$17.0M5 Dec 31, 2025$17.8M5 Dec 31, 2024−4.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$63.0K5 Dec 31, 2025
Finished goods$63.0K5 Dec 31, 2025

Properties, in its own words

Office space is provided to us by DSS. The office space is 1,997 square feet. The lease term is from October 1, 2022 to September 30, 2026. The fee for this space was approximately $5,500 per month through September 2024, increased to approximately $7,000 per month in October 2024 and increased to approximately $8,000 in January 2025.

Item 2 of the 10-K filed Mar 11, 2026.4

Leadership

Who has led IMPACT BIOMEDICAL INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Frank D. Heuszel2024

President

  1. Frank D. Heuszel2024

Chief financial officer

  1. Todd D. Macko2024–now

Chief operating officer

  1. Mark Suseck2024
2025
Board members and other officers (8)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Biolife Sugar, Inc. Nevada3
  • DSS Biolife International, Inc. Nevada3
  • DSS Biomedical International, Inc. Nevada3
  • Global BioLife, Inc. Nevada3
  • Global BioMedical, Inc. Nevada3
  • Global Sugar Solutions, Inc. Nevada3
  • Happy Sugar, Inc. Nevada3
  • Impact Biolife Science, Inc. Nevada3
  • Sweet Sense, Inc. Nevada3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Oct 9, 20268-K Bylaws or fiscal year changed21
  2. Sep 17, 20268-K Regulation FD disclosure22
  3. Sep 15, 20268-K Regulation FD disclosure23
  4. Mar 4, 20268-K Entered a material agreement24
  5. Nov 6, 20258-K Shareholder vote25
  6. Oct 27, 20258-K Other events26
  7. Jul 28, 20258-K Entered a material agreement27
  8. Jun 23, 20258-K Entered a material agreement; Regulation FD disclosure28
  9. Apr 3, 20258-K Entered a material agreement29
  10. Mar 28, 20258-K Entered a material agreement30
  11. Mar 13, 20258-K Executive or director change31
  12. Jan 29, 20258-K Regulation FD disclosure32
  13. Sep 16, 2024New chief executive Frank D. Heuszel becomes CEO11

Calendar

Coming up

  1. Nov 6, 2026Reports results for the quarter ending Sep/202633

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

137 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 18 major events, 29 insider forms, 2 large holders, 75 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Sep 24, 20264 EDGAR
  3. Sep 17, 20268-K EDGAR
  4. Sep 15, 20268-K EDGAR
  5. Aug 7, 202610-Q EDGAR
  6. May 12, 202610-Q EDGAR
  7. Apr 29, 2026144 EDGAR
  8. Apr 22, 2026S-8 POS EDGAR
  9. Apr 6, 2026S-8 POS EDGAR
  10. Mar 30, 20264 EDGAR
  11. Mar 25, 20264 EDGAR
  12. Mar 11, 202610-K EDGAR
  13. Mar 4, 20268-K EDGAR
  14. Jan 6, 20264 EDGAR
  15. Dec 30, 2025DEF 14C EDGAR
  16. Dec 11, 2025PRE 14C EDGAR
  17. Nov 7, 202510-Q EDGAR
  18. Nov 6, 20258-K EDGAR
  19. Oct 27, 20258-K EDGAR
  20. Sep 22, 2025DEF 14A EDGAR

The 137 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 7 buys and 25 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 24, 2026DSS, INC.10% ownerSale156$7.06$1.1KForm 4
Sep 23, 2026DSS, INC.10% ownerSale27$6.95$188Form 4
Sep 22, 2026DSS, INC.10% ownerSale723$0.55$398Form 4
Mar 27, 2026Macko Todd DChief Financial OfficerSale43,400$0.56$24.3KForm 4
Mar 25, 2026Macko Todd DChief Financial OfficerSale1,600$0.60$960Form 4
Mar 23, 2026Grady JasonDirectorSale50,000$0.65$32.5KForm 4
May 27, 2025DSS, INC.10% ownerSale45,400$0.54$24.5KForm 4
May 27, 2025DSS, INC.10% ownerSale45,400$0.54$24.5KForm 4
May 22, 2025DSS, INC.10% ownerSale115,600$0.55$63.6KForm 4
May 22, 2025DSS, INC.10% ownerSale115,600$0.55$63.6KForm 4
Apr 4, 2025DSS, INC.10% ownerSale890,800$0.95$846.3KForm 4
Apr 4, 2025Alset Inc.10% ownerSale180,000$0.96$172.8KForm 4
Apr 3, 2025Chan Heng Fai AmbroseDirectorSale351,555$0.50$175.8KForm 4
Apr 3, 2025Alset Inc.10% ownerSale624,917$0.67$417.1KForm 4
Apr 2, 2025Alset Inc.10% ownerSale884,776$0.60$531.4KForm 4
Apr 1, 2025Alset International Ltd10% ownerSale2,226,918$1.17$2.6MForm 4
Mar 31, 2025Alset International Ltd10% ownerSale300,000$1.03$309.0KForm 4
Mar 27, 2025DSS, INC.10% ownerSale47,681$2.50$119.2KForm 4
Mar 26, 2025DSS, INC.10% ownerSale58,139$3.13$182.2KForm 4
Mar 21, 2025DSS, INC.10% ownerSale499,800$3.30$1.6MForm 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Fai ChanSCHEDULE 13D/A, 2 filings Apr 2, 2025 to Apr 4, 202534

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Mark SuseckChief Operating Officer$126.7K$158.7K35
2024Frank D. HeuszelChief Executive Officer69$43.7K$54.8K35
2024Todd D. MackoChief Financial Officer$55535

SEC filer profile

How IMPACT BIOMEDICAL INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARIMPACT BIOMEDICAL INC.1
  • CIK0001834105
  • Employer ID (EIN)85-39269444
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inNevada4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address275 Wiregrass Pkwy,, West Henrietta, NY 145861
  • Phone585 232 15001
  • Shares outstanding107,821,231 as of Aug 4, 202610
  • Public float$7.6M as of Jun 30, 20254
  • AuditorGRASSI & CO., CPAs, P.C., Jericho, New York PCAOB ID 6064
  • On EDGAR sinceFeb 12, 20211
  • Filings143 in all: CORRESP (24), S-1/A (21), 8-K (18), 4 (17), UPLOAD (15), 3 (11), 10-Q (10), 10-K (3)1
    All 24 form types

    DEF 14C (3), PRE 14C (3), 425 (2), EFFECT (2), S-1 (2), S-8 POS (2), 144 (1), 3/A (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), CERT (1), DEF 14A (1), S-8 (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 11, 2026
    Quarterly report (10-Q) Aug 7, 2026
    Proxy statement (DEF 14A) Sep 22, 2025
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per share

From the cover page of the 10-K filed Mar 11, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks IMPACT BIOMEDICAL INC. names in Item 1A of its 10-K filed Mar 11, 2026: 26 risks under these headings, as written.4

  • Risks Related to Liquidity, the Company’s Business and Industry
  • If we do not adequately protect our intellectual property rights, our operations may be materially harmed.
  • New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease any potential revenue we might otherwise make.
  • Safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
  • Significant challenges or delays in our innovation and development of new products, technologies and indications could have an adverse impact on our long-term success.
  • We are subject to risks related to corporate social responsibility and reputational matters.
  • We may not have adequate funds to implement our business plan.
  • Our ability to resell and/or license our products will depend upon successful clinical trials.
  • We face significant competition from other biopharmaceutical and consumer product companies.
  • We are dependent on our collaborative agreements for the development of products and business development, which exposes us to the risk of reliance on the viability of third parties.
  • We are a human healthcare and consumer wellness company with no significant revenue. We have incurred operating losses since our inception, and we expect to incur losses for the foreseeable future and may never achieve profitability.
  • We are increasingly dependent on information technology systems to operate our business and a cyber-attack or other breach of our systems, or those of third parties on whom we may rely, could subject us to liability or interrupt the operation of our business.
The other 15 risks
  • If we are unable to obtain U.S. and/or foreign regulatory approval, we will be unable to resell or license our drug candidates.
  • We will rely on third parties for manufacturing of our clinical drug supplies; our dependence on these manufacturers may impair the development of our drug candidates.
  • Risks Related to Intellectual Property Rights
  • We rely on various intellectual property rights, including patents and licenses, in order to operate our business.
  • The Company could be negatively impacted if found to have infringed on intellectual property rights.
  • We rely heavily on our technology and intellectual property, but we may be unable to adequately or cost-effectively protect or enforce our intellectual property rights, thereby weakening our competitive position and increasing operating costs.
  • We rely on agreements with third parties to provide certain services, goods, technology, and intellectual property rights necessary to enable us to implement some of our applications.
  • If any third-party owners of intellectual property we may license in the future do not properly maintain or enforce the patents underlying such licenses, our competitive position and business prospects will be harmed.
  • Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property.
  • Risks Related to Ownership of Our Securities
  • The market price of our common stock may be highly volatile, and you could lose all or part of your investment.
  • We do not anticipate paying any dividends in the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.
  • Our certificate of incorporation grants our Board of Directors the power to designate and issue additional shares of common and/or preferred stock.
  • We are an “emerging growth company” under the federal securities laws and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.
  • If we fail to comply with the continued listing standards of the NYSE American LLC Exchange, it may result in a delisting of our common stock from the exchange.
  • If we are delisted from the NYSE American, your ability to sell your shares of our common stock may be limited by the penny stock restrictions, which could further limit the marketability of your shares.
  • If our common stock is not listed on a national securities exchange, compliance with applicable state securities laws may be required for certain offers, transfers and sales of the shares of our common stock.

Legal proceedings

There are no material proceedings to which any director or officer, or any associate of any such director or officer, is a party that is adverse to our Company or any of our subsidiaries or has a material interest adverse to our Company or any of our subsidiaries. No director or executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against it during the past ten years. No current director or executive officer has been convicted of a criminal offense or is the subject of a pending criminal proceeding during the past ten years. No current director or executive officer has been the subject of any order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities during the past ten years. No current director or officer has been found by a court to have violated a federal or state securities or commodities law during the past ten years.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. The Company accrues for potential litigation losses when a loss is probable and estimable.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35